Induction Chemotherapy for Locally Advanced Esophageal Cancer
Autor: | Renata Colombo Bonadio, Guilherme Harada, T.B. de Castria, F.C.C. de Araújo, Ivan Cecconello, Carolina Ribeiro Victor, Flavio Roberto Takeda, Ulysses Ribeiro Junior, Rubens Antonio Aissar Sallum |
---|---|
Rok vydání: | 2019 |
Předmět: |
Adult
Male Oncology medicine.medical_specialty Esophageal Neoplasms medicine.medical_treatment Locally advanced Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Aged Retrospective Studies Aged 80 and over business.industry Proportional hazards model Standard treatment Induction chemotherapy Induction Chemotherapy Hematology Middle Aged Esophageal cancer medicine.disease Radiation therapy Esophagectomy 030220 oncology & carcinogenesis Adenocarcinoma Female 030211 gastroenterology & hepatology business Chemoradiotherapy |
Zdroj: | Journal of Gastrointestinal Cancer. 51:498-505 |
ISSN: | 1941-6636 1941-6628 |
DOI: | 10.1007/s12029-019-00266-1 |
Popis: | Concurrent chemoradiotherapy followed by surgery is the standard treatment for locally advanced esophageal cancer (EC), and the role of induction chemotherapy (IC) remains unclear. We aimed to study if the addition of IC to standard treatment increases the rate of pathologic complete response (pCR). We assembled a retrospective analysis of patients (pts) diagnosed with locally advanced EC and treated with preoperative chemoradiotherapy followed by esophagectomy (CRT+S), preceded or not by IC, between 2009 and 2017. Patients’ characteristics, tumor variables, and treatment outcomes were evaluated. The Kaplan-Meier method was used to estimate overall survival and the Cox proportional hazard model to evaluate prognostic factors. One hundred and three patients were studied, with a median age of 62 years (range 37–84). Seventy-five patients (73%) were male, 67 (65%) had squamous cell carcinoma, and 31 (30%) had adenocarcinoma. Forty-three patients (41.7%) received IC followed by CRT+S (IC+CRT+S). The most frequent IC consisted of paclitaxel and platinum chemotherapy (90%), and the median number of cycles was 2. All patients received CRT+S. Concurrent chemotherapy was a combination of paclitaxel and platinum in 94 patients (91%). There was no statistically significant difference in pCR between the IC group and the standard CRT+S group. The pCR was 41.9% and 46.7% in the IC+CRT+S and CRT+S groups (p = 0.628), respectively. In the multivariate analysis, pCR was an independent prognostic factor for time to treatment failure (TTF) (HR 0.35, p = 0.021), but not for overall survival (OS) (p = 0.863). The factor that significantly affected OS in the multivariate analysis was positive lymph node (HR 5.9, 95%, p = 0.026). Our data suggest that the addition of IC to standard CRT + S does not increase the pCR rate in locally advanced EC. No difference in OS was observed between pts. that received or not IC. Regardless of the treatment received, pts. achieving a pCR presented improved TTF. |
Databáze: | OpenAIRE |
Externí odkaz: |